These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 20861098)

  • 21. [Hope for patients with rare diseases--"orphan" drugs].
    Kuzelová M; Kubácková K; Palágyi M; Smíd M
    Cas Lek Cesk; 2006; 145(4):296-300. PubMed ID: 16639930
    [TBL] [Abstract][Full Text] [Related]  

  • 22. "Creating hope" and other incentives for drug development for children.
    Connor E; Cure P
    Sci Transl Med; 2011 Jan; 3(66):66cm1. PubMed ID: 21248312
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Orphan drugs--medications for patients with rare diseases].
    Thielke D; Thyssen JP; Hansen BJ
    Ugeskr Laeger; 2006 Jun; 168(23):2236-8. PubMed ID: 16768975
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Our moral obligations in caring for patients with orphan cancers.
    Fernandez CV
    CMAJ; 2007 Jan; 176(3):297, 299. PubMed ID: 17261816
    [No Abstract]   [Full Text] [Related]  

  • 25. Orphan drug development in China: progress and challenges.
    Zhang S; Chen L; Zhang Z; Zhao Y
    Lancet; 2019 Sep; 394(10204):1127-1128. PubMed ID: 31571591
    [No Abstract]   [Full Text] [Related]  

  • 26. [Estimated orphans].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 2012 Mar; 35(3):81. PubMed ID: 22452124
    [No Abstract]   [Full Text] [Related]  

  • 27. Drug repositioning for orphan diseases.
    Sardana D; Zhu C; Zhang M; Gudivada RC; Yang L; Jegga AG
    Brief Bioinform; 2011 Jul; 12(4):346-56. PubMed ID: 21504985
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of orphan drug policies in treating rare diseases.
    Weerasooriya SU
    Health Info Libr J; 2019 Jun; 36(2):179-184. PubMed ID: 30933412
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Care in the treatment of orphan diseases at home].
    Bénévise N
    Soins; 2003; (672):49-51. PubMed ID: 12655827
    [No Abstract]   [Full Text] [Related]  

  • 30. PPPs succeeding in tackling neglected diseases.
    Frantz S
    Nat Rev Drug Discov; 2005 Oct; 4(10):796-7. PubMed ID: 16237841
    [No Abstract]   [Full Text] [Related]  

  • 31. The impact of the Orphan Drug Act on the development and advancement of neurological products for rare diseases: a descriptive review.
    Burke KA; Freeman SN; Imoisili MA; Coté TR
    Clin Pharmacol Ther; 2010 Oct; 88(4):449-53. PubMed ID: 20856241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lucrative niches: how drugs for rare diseases became lifeline for companies.
    Anand G
    Wall St J (East Ed); 2005 Nov; ():A1, A18. PubMed ID: 16502531
    [No Abstract]   [Full Text] [Related]  

  • 33. A discrete choice experiment investigating preferences for funding drugs used to treat orphan diseases: an exploratory study.
    Mentzakis E; Stefanowska P; Hurley J
    Health Econ Policy Law; 2011 Jul; 6(3):405-33. PubMed ID: 21205401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is the current approach to reviewing new drugs condemning the victims of rare diseases to death? A call for a national orphan drug review policy.
    Clarke JT
    CMAJ; 2006 Jan; 174(2):189-90. PubMed ID: 16415465
    [No Abstract]   [Full Text] [Related]  

  • 35. [Orphan diseases and orphan medicines: a Belgian and European study].
    Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
    J Pharm Belg; 2009 Dec; (4):131-7. PubMed ID: 20183989
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Orphanet and the Dutch Steering Committee Orphan Drugs. A European and Dutch databank of information on rare diseases].
    Liem SL
    Ned Tijdschr Tandheelkd; 2008 Nov; 115(11):621-3. PubMed ID: 19058507
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Crafting a robust business model for orphan drug development.
    Philippidis A
    Hum Gene Ther; 2011 Jul; 22(7):781-3. PubMed ID: 21756074
    [No Abstract]   [Full Text] [Related]  

  • 38. Drugs for rare diseases: mixed assessment in Europe.
    Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drugs for rare diseases: influence of orphan designation status on price.
    Picavet E; Dooms M; Cassiman D; Simoens S
    Appl Health Econ Health Policy; 2011 Jul; 9(4):275-9. PubMed ID: 21682354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pfizer explores rare disease path.
    Shaffer C
    Nat Biotechnol; 2010 Sep; 28(9):881-2. PubMed ID: 20829809
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.